Results 21 to 30 of about 71 (52)

Gastric Cancer: Pathobiology and Therapeutics

MedComm, Volume 7, Issue 6, June 2026.
Gastric cancer is a multistep process driven by the interplay of microbial virulence, host epithelial injury, and evolving molecular reprogramming. Initiation involves pathogen‐induced epigenetic alterations and the early subversion of key oncogenic signaling networks, facilitating the transition from chronic injury to metaplasia and malignant ...
Ruixian Yu, Miao Zhang, Yan Meng, Chunxiao Zhu, Weihong Zhang, Hui Zhang, Zhifa Cao, Meihang Du, Zhangting Zhao, Junping Bai, Yi Han, Yang Tang, Wei Kang, Ka Fai To, Shi Jiao, Liwei An, Zhaocai Zhou   +16 more
wiley   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice

Clinical and Translational Medicine, Volume 15, Issue 4, April 2025.
Angiogenesis plays a key role in tumour progression, invasion and metastasis, so strategies targeting angiogenesis are gradually becoming an important direction in cancer therapy. Interactions between endothelial cells and stromal cells and immune cells in the tumour microenvironment are significant in angiogenesis.
Shuaixi Yang, Yingshuai Fang, Yangcheng Ma, Fuqi Wang, Yuhang Wang, Jiachi Jia, Yabing Yang, Weipeng Sun, Quanbo Zhou, Zhen Li   +9 more
wiley   +1 more source

Current status and perspectives of esophageal cancer: a comprehensive review

Cancer Communications, Volume 45, Issue 3, Page 281-331, March 2025.
Abstract Esophageal cancer (EC) continues to be a significant global health concern, with two main subtypes: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Prevention and changes in etiology, improvements in early detection, and refinements in the treatment have led to remarkable progress in the outcomes of EC patients in the past ...
Wei Jiang, Bo Zhang, Jiaqi Xu, Liyan Xue, Luhua Wang   +4 more
wiley   +1 more source

Immunotherapy for gastric cancer: Advances and challenges

MedComm – Oncology, Volume 3, Issue 4, December 2024.
The article outlines four key immunotherapy strategies for gastric cancer: immune checkpoint inhibitors, CAR‐T cell therapy, cancer vaccines, and immunomodulators. These approaches enhance immune detection and elimination of cancer cells by blocking immune evasion, engineering T cells, stimulating targeted responses, and modifying the tumor ...
Pei Zhang, Chenyan Zhang, Xiaoying Li, Chen Chang, Cailing Gan, Tinghong Ye, Dan Cao   +6 more
wiley   +1 more source

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

MedComm, Volume 5, Issue 11, November 2024.
Potential strategies and potential targets for treating EC. Current the EC's research focuses on pivotal genes EGFR, HER2, TP53, CDKN2A, and APC, targeting key pathways in cell regulation and signaling. We highlight four novel therapeutic strategies: combined targeted therapy with chemotherapy, radiotherapy, immunotherapy, and multitarget approaches ...
Wenjing Wang, Lisha Ye, Huihui Li, Weimin Mao, Xiaoling Xu   +4 more
wiley   +1 more source

One Health: Therapies Targeting Genetic Variants in Human and Canine Histiocytic and Dendritic Cell Sarcomas

Veterinary and Comparative Oncology, Volume 22, Issue 3, Page 322-339, September 2024.
ABSTRACT The precise cause of HS/DCS is still unknown. The relatively low incidence in humans urges for an animal model with a high incidence to accelerate knowledge about genetics and optimal treatment of HS/DCS. Namely, until now, the therapies targeting genetic variants are still more experimental and sparsely used, while consensus is missing.
Suzanne Agnes Erich, Erik Teske
wiley   +1 more source

Clinical and translational research on cancer of the stomach and gastroesophageal junction: A pathologist's view

Clinical and Translational Discovery, Volume 4, Issue 4, August 2024.
(A) Adenocarcinoma of the stomach and gastroesophageal junction is a heterogeneous disease with considerable interindividual genetic and phenotypic differences, which influence prognosis and therapeutic success. (B) Treatment options and the associated use of predictive biomarkers are increasing.
Christoph Röcken
wiley   +1 more source

Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer

Health Science Reports, Volume 7, Issue 7, July 2024.
Abstract Background Gastric cancer (GC), a malignant epithelial tumor, is the fourth leading cause of cancer‐related death worldwide. Therapeutic strategies for GC, despite the biggest challenges, can significantly improve survival rates through early detection and effective screening methods.
Ousman Mohammed, Solomon Tebeje Gizaw, Maria Degef   +2 more
wiley   +1 more source

Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma

Pathology International, Volume 74, Issue 6, Page 301-316, June 2024.
Abstract Gastric cancers frequently harbor striking histological complexity and diversity between lesions as well as within single lesions, known as inter‐ and intratumoral heterogeneity, respectively. The latest World Health Organization Classification of Tumors designated more than 30 histological subtypes for gastric epithelial tumors, assigning 12 ...
Takeshi Kuwata
wiley   +1 more source